4.9 Animal Disease Models in Pharmacological Research
4.9 Animal Disease Models in Pharmacological Research contains 11 topic pages in Phase 4 — In-Vivo Animal Studies & Study Design.
Topic Group
Topics
Continue through the related topic pages.
4.9.1 Central Nervous System and Behavioural Disease Models
Central nervous system disease models are amongst the most extensively used in pharmacological research because behavioural and electrophysiological...
4.9.2 Cardiovascular Disease Models
Cardiovascular disease models allow the efficacy of candidate antihypertensive, anti-ischaemic, and cardioprotective agents to be evaluated using readily...
4.9.3 Metabolic and Endocrine Disease Models
Metabolic disease models are central to antidiabetic, anti-obesity, and lipid-lowering drug development, and increasingly incorporate dietary as well as...
4.9.4 Inflammatory, Immunological, and Pain Models
Inflammatory and immune-mediated disease models range from acute, hours-long assays suited to high-throughput screening of anti-inflammatory candidates to...
4.9.5 Oncology Models
Cancer pharmacology models range from chemically induced carcinogenesis models, which recapitulate the multistep process of tumourigenesis over an extended...
4.9.6 Organ Toxicity Models
Organ-specific toxicity models are used both to study the mechanisms of drug-induced organ injury and, extensively, to screen candidate hepatoprotective,...
4.9.7 Respiratory Disease Models
Respiratory disease models are used to evaluate candidate bronchodilator, anti-inflammatory, and disease-modifying agents for asthma and chronic obstructive...
4.9.8 Gastrointestinal Disease Models
Gastrointestinal disease models evaluate candidate antiulcer, gastroprotective, and anti-inflammatory bowel disease agents using endpoints ranging from...
4.9.9 Dermatological and Wound Models
Dermatological models evaluate candidate wound-healing, anti-psoriatic, and burn-management agents using standardised wound or lesion protocols amenable to...
4.9.10 Infectious Disease Models
Infectious disease models require appropriately biosafety-contained facilities and are used to evaluate candidate antimicrobial, antiparasitic, antifungal,...
4.9.11 General Toxicological Screening Models
Acute Oral Toxicity — LD50 Screening Model Beyond the disease-specific efficacy models described above, every candidate pharmacological agent must...